Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.07
- Piotroski Score 3.00
- Grade Buy
- Symbol (ARCT)
- Company Arcturus Therapeutics Holdings Inc.
- Price $23.18
- Changes Percentage (5.22%)
- Change $1.15
- Day Low $21.57
- Day High $23.55
- Year High $45.00
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
- Last Earnings 12/27/2012
- Ex-Dividend for 5/16 Dividend 01/08/2013
- Dividend Payable 01/15/2013
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $66.00
- High Stock Price Target $140.00
- Low Stock Price Target $14.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.03
- Trailing P/E Ratio -7.9
- Forward P/E Ratio -7.9
- P/E Growth -7.9
- Net Income $-29,725,000
Income Statement
Quarterly
Annual
Latest News of ARCT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
India will not buy from Russia's sanctioned Arctic LNG 2 project, oil secretary says
India will not purchase liquefied natural gas from Russia's Arctic LNG 2 project due to Western sanctions. The project by Novatek faces restrictions over Russia's conflict with Ukraine, with the US sa...
By Yahoo! Finance | 3 days ago -
In the gateway to the Arctic, fat, ice and polar bears are crucial. All three are in trouble - Winnipeg | Globalnews.ca
Geoff York, a biologist, warns of the declining polar bear population in Western Hudson Bay due to climate change. With only about 600 bears left, the ecosystem is transforming, affecting other specie...
By Global News | 6 days ago -
In the gateway to the Arctic, fat, ice and polar bears are crucial. All three are in trouble.
Biologist Geoff York warns that polar bears in Western Hudson Bay are facing a dire future due to climate change. With a declining population, the ecosystem is shifting, impacting various species. The...
By AP NEWS | 6 days ago
